AtriCure Statistics
Total Valuation
AtriCure has a market cap or net worth of $1.60 billion. The enterprise value is $1.51 billion.
Important Dates
The last earnings date was Tuesday, February 17, 2026, after market close.
| Earnings Date | Feb 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AtriCure has 49.72 million shares outstanding. The number of shares has increased by 1.67% in one year.
| Current Share Class | 49.72M |
| Shares Outstanding | 49.72M |
| Shares Change (YoY) | +1.67% |
| Shares Change (QoQ) | +1.99% |
| Owned by Insiders (%) | 3.51% |
| Owned by Institutions (%) | 100.28% |
| Float | 47.97M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 256.70 |
| PS Ratio | 3.00 |
| Forward PS | 2.62 |
| PB Ratio | 3.14 |
| P/TBV Ratio | 7.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.83 |
| EV / EBITDA | 136.08 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.96, with a Debt / Equity ratio of 0.16.
| Current Ratio | 3.96 |
| Quick Ratio | 2.87 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | 5.85 |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -2.40% and return on invested capital (ROIC) is -2.34%.
| Return on Equity (ROE) | -2.40% |
| Return on Assets (ROA) | -0.93% |
| Return on Invested Capital (ROIC) | -2.34% |
| Return on Capital Employed (ROCE) | -1.65% |
| Weighted Average Cost of Capital (WACC) | 11.44% |
| Revenue Per Employee | $411,175 |
| Profits Per Employee | -$8,806 |
| Employee Count | 1,300 |
| Asset Turnover | 0.85 |
| Inventory Turnover | 1.74 |
Taxes
In the past 12 months, AtriCure has paid $1.29 million in taxes.
| Income Tax | 1.29M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.20% in the last 52 weeks. The beta is 1.41, so AtriCure's price volatility has been higher than the market average.
| Beta (5Y) | 1.41 |
| 52-Week Price Change | -21.20% |
| 50-Day Moving Average | 38.75 |
| 200-Day Moving Average | 35.31 |
| Relative Strength Index (RSI) | 34.58 |
| Average Volume (20 Days) | 794,604 |
Short Selling Information
The latest short interest is 2.51 million, so 5.05% of the outstanding shares have been sold short.
| Short Interest | 2.51M |
| Short Previous Month | 2.51M |
| Short % of Shares Out | 5.05% |
| Short % of Float | 5.23% |
| Short Ratio (days to cover) | 4.92 |
Income Statement
In the last 12 months, AtriCure had revenue of $534.53 million and -$11.45 million in losses. Loss per share was -$0.24.
| Revenue | 534.53M |
| Gross Profit | 400.78M |
| Operating Income | -9.45M |
| Pretax Income | -10.16M |
| Net Income | -11.45M |
| EBITDA | 11.12M |
| EBIT | -9.45M |
| Loss Per Share | -$0.24 |
Full Income StatementBalance Sheet
The company has $167.43 million in cash and $76.50 million in debt, with a net cash position of $90.93 million or $1.83 per share.
| Cash & Cash Equivalents | 167.43M |
| Total Debt | 76.50M |
| Net Cash | 90.93M |
| Net Cash Per Share | $1.83 |
| Equity (Book Value) | 491.94M |
| Book Value Per Share | 10.26 |
| Working Capital | 241.00M |
Full Balance SheetMargins
Gross margin is 74.98%, with operating and profit margins of -1.77% and -2.14%.
| Gross Margin | 74.98% |
| Operating Margin | -1.77% |
| Pretax Margin | -1.90% |
| Profit Margin | -2.14% |
| EBITDA Margin | 2.08% |
| EBIT Margin | -1.77% |
| FCF Margin | n/a |
Dividends & Yields
AtriCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.67% |
| Shareholder Yield | -1.67% |
| Earnings Yield | -0.71% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AtriCure is $51.17, which is 58.62% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $51.17 |
| Price Target Difference | 58.62% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 14.00% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AtriCure has an Altman Z-Score of 6.75 and a Piotroski F-Score of 3.
| Altman Z-Score | 6.75 |
| Piotroski F-Score | 3 |
